Athersys Inc. extends agreement with Healios for a license to MultiStem therapy for indications in China


Cleveland biotechnology company Athersys Inc. (Nasdaq: ATHX) is extending its time horizon for working with Japanese drugmaker Healios K.K. on a key project in China.

Athersys announced in a news release on Monday, Dec. 17, that it has extended Healios’ exclusive period to negotiate an option that would allow the Japanese company to obtain a license for the development and commercialization of Athersys’ MultiStem therapy for certain indications in China.

Click here to read the complete article.

Story excerpt provided by Crain’s Cleveland Business.

Written by Scott Suttell.

Originally published December 17, 2018.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: